Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6856 to 6870 of 7680 results

  1. Pelareorep for treating recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer [ID1099]

    Discontinued [GID-TA10688]

    Technology appraisal guidance
    Discontinued

  2. Rigosertib for previously treated high-risk myelodysplastic syndrome [ID805]

    Discontinued [GID-TA10709]

    Technology appraisal guidance
    Discontinued

  3. AT406 for neoadjuvant treatment of epithelial ovarian cancer [ID1428]

    Discontinued [GID-TA10809]

    Technology appraisal guidance
    Discontinued

  4. Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after alectinib or ceritinib [ID2702]

    Discontinued [GID-TA10569]

    Technology appraisal guidance
    Discontinued

  5. Pembrolizumab for previously treated endometrial cancer [ID1205]

    Discontinued [GID-TA10243]

    Technology appraisal guidance
    Discontinued

  6. Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]

    In development [GID-TA10851] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer [ID4006]

    In development [GID-TA10906] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]

    In development [GID-TA10899] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]

    In development [GID-TA10900] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]

    In development [GID-TA10728] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Diabetes - buccal insulin [ID311]

    Discontinued [GID-TAG244]

    Technology appraisal guidance
    Discontinued

  12. Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]

    Discontinued [GID-TAG363]

    Technology appraisal guidance
    Discontinued

  13. Lung cancer (non-small cell, advanced, inoperable) - liposomal cisplatin (with chemotherapy) [ID657]

    Discontinued [GID-TAG496]

    Technology appraisal guidance
    Discontinued

  14. Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]

    Discontinued [GID-TAG494]

    Technology appraisal guidance
    Discontinued

  15. ATIR101 with haploidentical haematopoietic stem cell transplantation for haematological cancers [ID1093]

    Discontinued [GID-TA10445]

    Technology appraisal guidance
    Discontinued